Centene’s stock suffers a historic plunge as underestimation of healthcare costs leads the insurer to withdraw its full-year ...

A Deutsche Bank survey is asking investors what they're looking for on July 9, when a pause on the so-called reciprocal ...

U.S. stock futures remain flat on Wednesday morning after economic data showed private sector hiring unexpectedly contracted in June. Private payrolls lost 33, ...

The U.S. dollar softened on Wednesday, erasing an early advance, after the latest reading on private payrolls from ADP showed an unexpected decline. The ICE U.S. Dollar Index, was flat in recent trade ...

UniFirst logged higher profit and revenue in its fiscal third quarter and said costs tied to ongoing initiatives are likely to come in below expectations. The uniform supplier on Wednesday posted net ...

Treasury yields retreated from their highest levels early Wednesday after the latest monthly data on private payrolls from ADP showed an unexpected contraction. The yield on the 10-year note was up 3 ...

Privately run businesses reduced jobs in June for the first time in more than two years, as ongoing U..S. trade wars created a “hesitancy to hire and a reluctance to replace departing workers,” the ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

CytoSorbents plans to ask Canadian health authorities to reconsider rejecting the company's license application for DrugSorb-ATR, an investigational device designed to reduce the severity of bleeding ...

BrightView Holdings shares declined 8.8% in premarket trading following lowered guidance for fiscal 2025. Shares were trading around $15.37. The stock is up 5.4% on the year.

The Cboe Volatility index, or VIX, is below 17 and near its lowest levels since the stock market hit its previous peak in mid February. The VIX is an option-derived measure of expected S&P 500 ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.